Liver Disease Diagnostics Market Size - By Disease Type (Hepatitis, Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease (NAFLD)), Technique (Imaging, Liver Biopsy, Endoscopy, Lab Test), End-use – Global Forecast (2024 – 2032)

Liver Disease Diagnostics Market Size - By Disease Type (Hepatitis, Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease (NAFLD)), Technique (Imaging, Liver Biopsy, Endoscopy, Lab Test), End-use – Global Forecast (2024 – 2032)

Liver Disease Diagnostics Market Size

Liver Disease Diagnostics Market size was valued at around USD 39.5 billion in 2023 and is estimated to grow at 7.3% CAGR from 2024 to 2032. The increasing prevalence of liver diseases, growing awareness regarding liver related complications and the importance of early diagnosis, rising geriatric population, and continuous advancements in diagnostic technologies.
 

Moreover, the high prevalence of liver diseases, such as non-alcoholic fatty liver disease (NAFLD), viral hepatitis, and liver cirrhosis, is a major concern for people with sedentary lifestyles and weak immunity. Obesity, viral infections, alcohol and drug consumption, among other factors are contributing to the rising burden of liver disorders in the world. For instance, as per the article published by Clinical and Molecular Hepatology, NAFLD affects around 32% of individuals worldwide, with a greater incidence among males (40%) than females (26%).
 

Liver disease diagnostics refer to the various methods and procedures employed to identify, assess, and monitor diseases or conditions affecting the liver. The liver is a vital organ responsible for numerous functions, including detoxification, metabolism, and the production of proteins necessary for blood clotting. Liver diseases encompass a wide range of conditions, such as hepatitis, cirrhosis, fatty liver disease, and liver cancer.
 

Liver Disease Diagnostics Market Trends

Numerous factors are influencing the dynamics and expansion of the industry. These trends reflect the surging demand for integration of  artificial intelligence (AI) in healthcare and machine learning in liver disease, rising focus on viral hepatitis testing, and growing need for point-of-care testing, among other factors.
 

• Non-invasive methods of diagnosis are growing increasingly popular for liver illnesses. Elastography, transient elastography (FibroScan), magnetic resonance elastography (MRE), and shear wave elastography are all techniques used to precisely determine liver fibrosis without requiring invasive procedures like liver biopsy.
   
• Moreover, early detection and preventive measures are highly prioritized in the treatment of liver related diseases. Early detection enables quick treatment and reduction of disease growth.
   

Liver Disease Diagnostics Market Analysis

The market by disease type is segmented into hepatitis, cirrhosis, liver cancer, non-alcoholic fatty liver disease (NAFLD), and other disease types. The hepatitis segment accounted for majority revenue share and was valued at around USD 13.1 billion revenue in 2023.
 

• Chronic hepatitis B and C infections are major risk factors for developing hepatocellular carcinoma (HCC), a form of primary liver cancer. The growing prevalence of HCC focuses on the importance of early detection, monitoring and employing hepatitis and liver cancer diagnostics to improve patient outcomes in diagnostics. For instance, according to the North American Association of Central Cancer Registries (NAACCR), 41,210 new HCC cases were diagnosed in the U.S. in 2023.
   
• Moreover, hepatitis B infection in pregnant women can lead to the transmission of the virus to newborns. Screening and timely intervention are crucial to prevent mother-to-child transmission, emphasizing the need for effective hepatitis diagnostics in maternal and neonatal health.

Based on technique, the liver disease diagnostics market is categorized into imaging, liver biopsy, endoscopy, and laboratory tests. The laboratory tests segment dominated the market and accounted for over 38.1% market share in 2023.
 

• Routine liver function tests, including measures of liver enzymes (ALT, AST, ALP), bilirubin, and albumin, are essential for assessing the overall health of the liver. These tests are commonly prescribed in various clinical settings to screen for liver diseases, contributing to the consistent demand for laboratory testing.
   
• Additionally, liver disease testing is becoming more accurate, efficient, and rapid owing to consistent advances in laboratory diagnostic technology, such as automated analyzers, immunoassays, and molecular diagnostic techniques. Continuous advancement increases the capability of laboratory testing.
   

The liver disease diagnostics market by end-use is categorized into hospitals, laboratories, and other end-users. The hospitals segment accounted for over USD 20.8 billion revenue in 2023.
 

• Hospitals provide comprehensive care for patients with liver diseases, and diagnostics are a crucial component of this care. From routine screening to advanced diagnostics for complex cases, hospitals offer a wide range of liver disease diagnostic services.
   
• Furthermore, hospitals typically house advanced imaging facilities, such as CT scans, MRI, and ultrasound, which are essential for liver disease diagnostics. Additionally, hospitals perform liver biopsies and other invasive diagnostic procedures to obtain accurate information about liver health.

North America liver disease diagnostics market accounted for USD 16.2 billion revenue in 2023 and is estimated to witness substantial market expansion over the analysis timeline.
 

• North America has one of the world's highest obesity rates, that is a key risk factor for liver disease. The obesity pandemic increases the prevalence of disorders such as NAFLD and liver steatosis, thus, boosting the demand for liver disease diagnostics.
   
• Furthermore, the region has excellent healthcare infrastructure, including cutting-edge diagnostic centres and hospitals. The availability of advanced imaging technologies, laboratories, and specialised hepatology departments.
   

Liver Disease Diagnostics Market Share

The liver disease diagnostics industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced diagnostic kits based on different technologies is among a key market strategy. Some of the leading industry players including Abbott Laboratories, BioMerieux SA, Bio-Rad Laboratories Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., among others have a notable presence in the market.
 

Liver Disease Diagnostics Market Companies

Some of the eminent market participants operating in the liver disease diagnostics industry include

• Abbott Laboratories
• BioMerieux SA
• Bio-Rad Laboratories Inc.
• Cosara Diagnostics Pvt Ltd.
• F. Hoffmann-La Roche Ltd.
• HORIBA Medical
• Laboratory Corporation of America Holdings
• Meril Life Sciences Pvt. Ltd.
• Qiagen N.V.
• Siemens Healthcare GmbH
• Thermo Fisher Scientific Inc.
   

Liver Disease Diagnostics Industry News

• In May 2021, GENFIT announced the launch of NASHnext, an innovative noninvasive diagnostic test for nonalcoholic steatohepatitis (NASH). It is driven by NIS4, GENFIT's unique diagnostic technology that uses a new, blood-based molecular biomarker test to detect NASH and substantial fibrosis, also referred to as at-risk NASH, in patients with at least one metabolic risk factor.
   
• In November 2019, Siemens Healthineers has announced the launch of its Enhanced Liver Fibrosis (ELF) diagnostic service in the U.S. It enables the detection of chronic liver disease in patients, especially nonalcoholic fatty liver disease (NAFLD).
   

Liver disease diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Disease Type

• Hepatitis
• Cirrhosis
• Liver cancer
• Non-alcoholic fatty liver disease (NAFLD)
• Other disease types

By Technique

• Imaging
• Liver biopsy
• Endoscopy
• Laboratory tests

By End-use

• Hospitals
• Laboratories
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa